<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03605654</url>
  </required_header>
  <id_info>
    <org_study_id>MDR-102-mMLK</org_study_id>
    <nct_id>NCT03605654</nct_id>
  </id_info>
  <brief_title>Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants</brief_title>
  <official_title>A Phase 2/3, Prospective, Randomized, Multi-center, Open-Label, Controlled Trial to Assess the Efficacy &amp; Safety of Cellular Immunotherapy With MDR-102 for Induction of Immune Quiescence™in Recipients of HLA-mismatched, LD Kidney Transplants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medeor Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medeor Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Phase 2 primary objective is to evaluate achievement of persistent mixed chimerism and&#xD;
      withdrawal of at least one immunosuppression drug for a minimum of 6 months with no episodes&#xD;
      of biopsy-proven acute rejection or transplant kidney loss induced by cellular immunotherapy&#xD;
      with MDR-102 in recipients of 1, 2, or 3 out of 6 human leukocyte antigen (HLA)-mismatched,&#xD;
      living donor kidney transplants.&#xD;
&#xD;
      The Phase 3 primary objective is to evaluate achievement of induction of immune quiescence by&#xD;
      cellular immunotherapy with MDR-102 in recipients of 1, 2, or 3 out of 6 HLA-mismatched,&#xD;
      living donor kidney transplants. Immune quiescence is defined as remaining on maintenance&#xD;
      immunosuppression monotherapy with Tac or CsA for 12 months or more after completion of&#xD;
      anti-rejection immunosuppression drug therapy reduction with no episodes of biopsy-proven&#xD;
      acute rejection, transplant kidney loss, or subject deat.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, patients receiving a transplanted kidney are required to take life-long&#xD;
      immunosuppressive medications to prevent rejection of the transplanted kidney. These&#xD;
      medications carry substantial side effects. In addition, these medicines often do not&#xD;
      completely control damage to the kidney from the recipients' immune system, ultimately&#xD;
      causing the kidney to fail.&#xD;
&#xD;
      Medeor Therapeutics is developing a novel cell-based therapy as personalized cellular&#xD;
      immunotherapies to improve outcomes in organ transplant recipients.&#xD;
&#xD;
      The purpose of the current Phase 2/3 study is to demonstrate the efficacy and safety of&#xD;
      MDR-102 for the induction of immune quiescence in a prospective, randomized, open-label,&#xD;
      multi-center clinical trial. MDR-102 is intended to induce mixed lymphohematopoietic&#xD;
      chimerism and donor specific immune quiescence in order to preserve transplant kidney&#xD;
      function, avert transplant kidney rejection, and reduce the cumulative and serious side&#xD;
      effects associated with immunosuppression drugs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A low-dose Total Lymphoid Irradiation and anti- thymocyte globulin combined with a single infusion of MDR-102</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 2 Primary Outcome: Achievement of persistent mixed chimerism and withdrawal of at least one Immunosuppression drug for a minimum of 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Persistent mixed chimerism is defined as:&#xD;
• At least 6 months of persistent white blood cells mixed chimerism consisting of at least 5% donor white blood cells in whole blood or in at least one white blood cells lineage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 3 Primary Outcome: proportion of subjects achieving immune quiescence</measure>
    <time_frame>24 months</time_frame>
    <description>Immune quiescence is defined as:&#xD;
Achievement of the required duration of persistent donor mixed chimerism (i.e., 6 months) to permit mycophenolic acid drug (e.g., mycophenolate mofetil) immunosuppression stoppage without a taper at approximately 12 months post-kidney transplant surgery,&#xD;
Successful stoppage of mycophenolic acid drug (e.g., mycophenolate mofetil) at 12 + 1 months post-kidney transplant surgery, and&#xD;
Subsequent successful maintenance on calcineurin inhibitor monotherapy for at least 12 additional months (out to at least 24 months post-kidney transplant surgery) without biopsy-proven acute rejection, transplant kidney loss, or subject death</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Kidney Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Investigational Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A low-dose Total Lymphoid Irradiation and anti- thymocyte globulin combined with a single infusion of MDR-102 post-kidney transplant and standard anti-rejection medications in recipients of 1, 2, or 3 out of 6 human leukocyte antigen (HLA)-mismatched, living donor kidney transplants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard anti-rejection medications that would be given to kidney transplant recipients who are outside the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Randomized Exploratory Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A low-dose Total Lymphoid Irradiation and anti- thymocyte globulin combined with a single infusion of MDR-102 post-kidney transplant and standard anti-rejection medications in recipients of 4, 5, or 6 out of 6 human leukocyte antigen (HLA)-mismatched, living donor kidney transplants</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MDR-102</intervention_name>
    <description>Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells</description>
    <arm_group_label>Investigational Arm</arm_group_label>
    <arm_group_label>Non-Randomized Exploratory Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunosuppressive Agents</intervention_name>
    <description>Standard Anti-Rejection Medications that would be given to kidney transplant recipients who are outside the study</description>
    <arm_group_label>Active Control Arm</arm_group_label>
    <other_name>Corticosteroids</other_name>
    <other_name>Mycophenolate Mofetil</other_name>
    <other_name>Tacrolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recipient Inclusion Criteria:&#xD;
&#xD;
               -  Planned recipient of a first kidney allograft from an human leukocyte antigen&#xD;
                  (HLA)-matched, living related donor. Zero-mismatch transplants are excluded&#xD;
&#xD;
               -  Age ≥18 and ≤65 years&#xD;
&#xD;
               -  Single solid organ recipient (kidney only)&#xD;
&#xD;
               -  ABO compatibility with donor&#xD;
&#xD;
          -  Donor Inclusion Criteria:&#xD;
&#xD;
               -  Human leukocyte antigen (HLA)-mismatched first degree (parent, child or sibling)&#xD;
                  or second-degree (child of a sibling) relative of the prospective recipient&#xD;
                  participant. Zero-mismatch transplants are excluded&#xD;
&#xD;
               -  Age ≥18 and ≤65 years&#xD;
&#xD;
               -  Prepared to be a living related kidney donor, and capable of undergoing&#xD;
                  granulocyte-colony stimulating factor (G-CSF) mobilization and apheresis of&#xD;
                  hematopoietic cells&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recipient Exclusion Criteria:&#xD;
&#xD;
               -  Underlying kidney disease with a high risk of disease recurrence in the&#xD;
                  transplanted kidney&#xD;
&#xD;
               -  Baseline positive donor-specific anti-HLA antibody testing&#xD;
&#xD;
               -  Is taking immunosuppressive therapy&#xD;
&#xD;
               -  Prior hematopoietic cell transplant, organ transplant, any cell therapy, or any&#xD;
                  gene therapy&#xD;
&#xD;
               -  Evidence of prior hepatitis B (HBV) or hepatitis C (HCV)&#xD;
&#xD;
          -  Donor Exclusion Criteria:&#xD;
&#xD;
               -  History of autoimmune disorders&#xD;
&#xD;
               -  History of type 1 or type 2 diabetes mellitus&#xD;
&#xD;
               -  Tests confirmed positive for human immunodeficiency virus (HIV), HBV, HCV&#xD;
&#xD;
               -  History of infection with Zika virus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne Crowley, MS, BSN</last_name>
    <role>Study Director</role>
    <affiliation>Medeor Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lenuta Micsa, MD</last_name>
    <phone>646-239-9748</phone>
    <email>lmicsa@medeortx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suzanne Crowley, MS, BSN</last_name>
    <phone>321-266-9347</phone>
    <email>scrowley@medeortx.com</email>
  </overall_contact_backup>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2018</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

